Eleven Biotherapeutics Inc. (EBIO)

2.48
0.04 1.59
NASDAQ : Health Technology
Prev Close 2.52
Open 2.60
Day Low/High 2.38 / 2.63
52 Wk Low/High 0.62 / 3.50
Volume 1.82M
Avg Volume 3.68M
Exchange NASDAQ
Shares Outstanding 47.79M
Market Cap 126.64M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of June 15th Options Trading For Eleven Biotherapeutics (EBIO)

Investors in Eleven Biotherapeutics Inc saw new options begin trading this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EBIO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

Eleven Biotherapeutics Reports Fourth Quarter And Full-Year 2017 Operating Results And Vicinium Development Progress

Eleven Biotherapeutics Reports Fourth Quarter And Full-Year 2017 Operating Results And Vicinium Development Progress

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today reported key pipeline progress and operating...

Preliminary Data From Phase 3 VISTA Trial In Bladder Cancer To Be Presented In A Plenary Session At American Urological Association Annual Meeting

Preliminary Data From Phase 3 VISTA Trial In Bladder Cancer To Be Presented In A Plenary Session At American Urological Association Annual Meeting

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that preliminary efficacy and safety...

Eleven Biotherapeutics Announces Pricing Of $10.0 Million Offering Priced At-the-Market

Eleven Biotherapeutics Announces Pricing Of $10.0 Million Offering Priced At-the-Market

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that it has entered into a definitive...

Enrollment Completed In Phase 3 Registration Trial For Non-Muscle Invasive Bladder Cancer

Enrollment Completed In Phase 3 Registration Trial For Non-Muscle Invasive Bladder Cancer

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that the company has completed...

Eleven Biotherapeutics To Present At The Cowen And Company 38th Annual Health Care Conference

Eleven Biotherapeutics To Present At The Cowen And Company 38th Annual Health Care Conference

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, president...

Eleven Biotherapeutics Appoints Richard Fitzgerald As Chief Financial Officer

Eleven Biotherapeutics Appoints Richard Fitzgerald As Chief Financial Officer

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Richard F.

Eleven Biotherapeutics To Present At Biotech Showcase 2018

Eleven Biotherapeutics To Present At Biotech Showcase 2018

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President...

Eleven Biotherapeutics Announces Chief Scientific Officer To Chair A Session At The Antibody Engineering And Therapeutics Meeting

Eleven Biotherapeutics Announces Chief Scientific Officer To Chair A Session At The Antibody Engineering And Therapeutics Meeting

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Dr.

Eleven Biotherapeutics To Present At The LD Micro Main Event 2017

Eleven Biotherapeutics To Present At The LD Micro Main Event 2017

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President...

Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results

Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today reported financial results for the...

Eleven Biotherapeutics To Report Third Quarter 2017 Financial Results On November 14, 2017

Eleven Biotherapeutics To Report Third Quarter 2017 Financial Results On November 14, 2017

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced it will host a live...

Eleven Biotherapeutics To Present At Stifel 2017 Healthcare Conference

Eleven Biotherapeutics To Present At Stifel 2017 Healthcare Conference

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President...

Eleven Biotherapeutics Announces Closing Of $8.0 Million Underwritten Public Offering

Eleven Biotherapeutics Announces Closing Of $8.0 Million Underwritten Public Offering

Eleven Biotherapeutics, Inc. ("Eleven" or the "Company") (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced...

Eleven Biotherapeutics Prices Of $8.0 Million Underwritten Public Offering

Eleven Biotherapeutics Prices Of $8.0 Million Underwritten Public Offering

Eleven Biotherapeutics, Inc. ("Eleven" or the "Company") (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced...

Eleven Biotherapeutics Appoints Richard Fitzgerald As Interim Chief Financial Officer

Eleven Biotherapeutics Appoints Richard Fitzgerald As Interim Chief Financial Officer

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the appointment of Richard F.

Eleven Biotherapeutics Announces Completion Of Vicinium Manufacturing For Ongoing Clinical Trials In Non-Muscle Invasive Bladder Cancer

Eleven Biotherapeutics Announces Completion Of Vicinium Manufacturing For Ongoing Clinical Trials In Non-Muscle Invasive Bladder Cancer

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that it has completed the...

Eleven Biotherapeutics To Present At The Rodman & Renshaw 19th Annual Global Investment Conference

Eleven Biotherapeutics To Present At The Rodman & Renshaw 19th Annual Global Investment Conference

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that...

Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results

Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today reported financial...

Eleven Biotherapeutics To Report Second Quarter 2017 Financial Results On Monday, August 14, 2017

Eleven Biotherapeutics To Report Second Quarter 2017 Financial Results On Monday, August 14, 2017

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that it...

Eleven Biotherapeutics To Present At Canaccord Genuity 37th Annual Growth Conference

Eleven Biotherapeutics To Present At Canaccord Genuity 37th Annual Growth Conference

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that...

Eleven Biotherapeutics To Present At 2017 Marcum MicroCap Conference

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that...

Eleven Biotherapeutics To Collaborate With AstraZeneca And The National Cancer Institute On Development Of ViciniumTM In Combination With Durvalumab For The Treatment Of Non-Muscle Invasive Bladder Cancer

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the...

Eleven Biotherapeutics Announces Data And Safety Monitoring Board (DSMB) Recommendation To Continue Phase 3 Registration Trial With Vicinium™ In Non-Muscle Invasive Bladder Cancer Based On Review Of Safety And Efficacy Data

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that its...

Eleven Biotherapeutics Continues Expansion Of Clinical Development Team With Appointment Of David Brooks, M.D., Ph.D., To Senior Vice President, Clinical Development

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the...

Eleven Biotherapeutics Reports First Quarter 2017 Financial Results

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today reported financial...

Eleven Biotherapeutics To Report First Quarter 2017 Financial Results On Thursday, May 4, 2017

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that it...